

Corp. Office : SM House, 11 Sahakar Road, Vile Parle (East), Mumbai - 400 057, Tel.: (+91-22) 6726 1000,  
Fax: (+91-22) 6726 1067, Email : info@guficbio.com, Website: www.gufic.com

25/LG/SE/FEB/2026/GBSL

February 13, 2026

To  
The Listing Department  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort, Mumbai – 400 001  
**Scrip Code : 509079**

To  
The Listing Department  
**National Stock Exchange of India Limited**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
**Scrip Symbol : GUFICBIO**

**Subject: Outcome of the Board of Directors Meeting held on Friday, February 13, 2026**

Dear Sir/Madam,

Pursuant to Regulation 30 (read with Part A of Schedule III) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), we wish to inform that the Board of Directors of the Company at its meeting held today, i.e. on Friday, February 13, 2026, inter-alia, considered and approved the following matters:

**1. Approval of Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended December 31, 2025**

In terms of the provisions of Regulation 33 of Listing Regulations, we are enclosing herewith copy of the Unaudited Financial Results (Standalone and Consolidated) of the Company, for the quarter and nine months ended December 31, 2025 along with the Limited Review Report thereon as issued by Statutory Auditors, enclosed herewith as “Annexure A”.

**2. Further investment in Selvax Pty Ltd. (“Selvax”) by way of subscription of 3,78,350 Ordinary shares at AUD 20 cents per share, for a total consideration not exceeding USD 50,000**

The details required under Regulation 30 of the Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026 are enclosed herewith as “Annexure B”.

The meeting of the Board of Directors commenced at 06:30 p.m. and concluded at 08:00 p.m.

Kindly take the same on your record.

Thanking You,

Yours truly,  
**For Gufic Biosciences Limited**

**Pankaj Gandhi**  
**Whole Time Director**  
**DIN: 00001858**

*Encl.: As above*



**MITTAL AGARWAL & COMPANY**  
CHARTERED ACCOUNTANTS

Limited Review Report on the Standalone Unaudited Quarterly Financial Results of the Company  
Pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements)  
Regulations, 2015, as amended

Review Report to  
The Board of Directors  
Gufic Biosciences Limited

- 1) We have reviewed the accompanying statement of Standalone Unaudited Financial Results of **Gufic Biosciences Limited** (the "Company") for the quarter ended and nine months ended 31 December 2025 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2) This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
- 3) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit, and accordingly, we do not express an audit opinion.
- 4) Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Mittal Agarwal & Company  
Chartered Accountants  
(Firm Registration No. 131025W)



*Deepesh Mittal*

Deepesh Mittal

Partner

Membership No. 539486

Place: Mumbai

Dated: 13/02/2026

UDIN: 26539486BMLUDW2399



# MITTAL AGARWAL & COMPANY

CHARTERED ACCOUNTANTS

Limited Review Report on the Consolidated Unaudited Quarterly Financial Results of the Company Pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended

Review Report to  
The Board of Directors  
Gufic Biosciences Limited

- 1) We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Gufic Biosciences Limited** and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and nine months ended 31 December 2025 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
- 2) This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4) We also performed procedures in accordance with the Circular No. CIR/CFD/CMDI/44/20 19 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.
- 5) The Statement includes the result of the entities:

Name of the Entity	Relationship
Gufic UK Limited	Wholly Owned Foreign Subsidiary
Veira Life FZE	Wholly Owned Foreign Subsidiary
Gufic Ireland Limited	Wholly Owned Foreign Subsidiary
Gufic Prime Private Limited	Subsidiary

- 6) The financial results of wholly owned foreign subsidiaries have been prepared in accordance with the accounting principles generally accepted in their respective countries. The management of the Company has converted these financial results of such wholly owned foreign subsidiaries from their local accounting principles to Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013. Our conclusion, insofar as it relates to the balances and affairs of these subsidiaries located outside India, is based on the financial results/statements as certified by the management and the conversion adjustments prepared by them.

Our conclusion is not modified in respect of this matter.





# MITTAL AGARWAL & COMPANY

CHARTERED ACCOUNTANTS

- 7) Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



For Mittal Agarwal & Company  
Chartered Accountants  
(Firm Registration No. 131025W)

*Deepesh Mittal*

Deepesh Mittal

Partner

Membership No. 539486

Place: Mumbai

Dated: 13/02/2026

UDIN: 26539486CXFVWW811

## GUFIC BIOSCIENCES LIMITED

Regd. Office : 37, Kamala Bhavan II, S. Nityanand Road, Andheri (East), Mumbai - 400069  
(CIN- L24100MH1984PLC033519)

Website - [www.gufic.com](http://www.gufic.com), email - [corporaterelations@guficbio.com](mailto:corporaterelations@guficbio.com), Ph-022 67261000, Fax - 022 67261068

(Rs. in Lakhs except EPS)

### Unaudited Standalone and Consolidated Statement of Financial Results for the Quarter and Nine Months Ended December 31, 2025

Sr. No.	Particulars	Standalone						Consolidated						
		Quarter Ended			Nine Months Ended			Quarter Ended			Nine Months Ended			
		31-Dec-25	30-Sep-25	31-Dec-24	31-Dec-25	31-Dec-24	31-Mar-25	31-Dec-25	30-Sep-25	31-Dec-24	31-Dec-25	31-Dec-24	31-Mar-25	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1	<b>Income</b>													
a	Revenue from operations	23,109.36	23,041.80	20,779.39	68,842.31	61,478.58	81,980.60	23,140.99	23,705.45	20,779.39	69,218.69	61,478.58	81,980.60	
b	Other income	79.32	209.05	186.36	377.79	323.20	361.50	79.05	211.55	186.36	383.12	323.20	362.65	
	<b>Total Income</b>	<b>23,188.68</b>	<b>23,250.85</b>	<b>20,965.75</b>	<b>69,220.10</b>	<b>61,801.78</b>	<b>82,342.10</b>	<b>23,220.04</b>	<b>23,917.00</b>	<b>20,965.75</b>	<b>69,601.81</b>	<b>61,801.78</b>	<b>82,343.25</b>	
2	<b>Expenses</b>													
a	Cost of materials consumed	9,906.79	11,347.16	7,358.69	30,105.53	22,128.86	34,420.10	9,926.83	11,347.16	7,358.69	30,125.57	22,128.86	34,420.10	
b	Purchase of stock-in-trade	1,582.24	2,568.58	1,554.95	5,577.64	4,456.54	5,541.43	1,582.24	2,568.58	1,554.95	5,577.64	4,456.54	5,541.43	
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,406.90)	(3,925.32)	502.92	(5,080.06)	1,917.95	(2,491.42)	(1,406.90)	(3,471.89)	502.92	(5,080.06)	1,917.95	(2,491.42)	
d	Employee benefits expense	4,008.87	3,745.06	3,395.77	11,353.61	9,147.61	12,718.64	4,008.87	3,745.06	3,395.77	11,353.61	9,147.61	12,718.64	
e	Finance cost	835.60	958.45	490.91	2,717.41	1,471.18	2,451.90	835.60	958.45	490.91	2,717.41	1,471.18	2,451.90	
f	Depreciation and amortisation expense	769.21	777.29	461.81	2,318.39	1,322.11	2,106.44	769.20	777.30	461.82	2,318.39	1,322.12	2,106.46	
g	Other expenses	5,387.82	5,726.77	4,572.74	16,441.97	12,992.71	18,152.26	5,732.18	5,731.93	4,574.64	16,829.41	12,995.67	18,181.79	
	<b>Total Expenses</b>	<b>21,083.63</b>	<b>21,197.99</b>	<b>18,337.79</b>	<b>63,434.49</b>	<b>53,436.96</b>	<b>72,899.35</b>	<b>21,448.02</b>	<b>21,656.59</b>	<b>18,339.70</b>	<b>63,841.97</b>	<b>53,439.93</b>	<b>72,928.90</b>	
3	<b>Total Profit before exceptional items and tax (1-2)</b>	<b>2,105.05</b>	<b>2,052.86</b>	<b>2,627.96</b>	<b>5,785.61</b>	<b>8,364.82</b>	<b>9,442.75</b>	<b>1,772.02</b>	<b>2,260.41</b>	<b>2,626.05</b>	<b>5,759.84</b>	<b>8,361.85</b>	<b>9,414.35</b>	
4	Exceptional items	-	-	-	-	-	-	-	-	-	-	-	-	
5	<b>Total Profit Before Tax</b>	<b>2,105.05</b>	<b>2,052.86</b>	<b>2,627.96</b>	<b>5,785.61</b>	<b>8,364.82</b>	<b>9,442.75</b>	<b>1,772.02</b>	<b>2,260.41</b>	<b>2,626.05</b>	<b>5,759.84</b>	<b>8,361.85</b>	<b>9,414.35</b>	
6	<b>Tax expense</b>													
	Current tax	330.00	355.00	395.00	907.00	1,845.00	1,872.00	311.00	374.00	395.00	907.00	1,845.00	1,872.00	
	Deferred tax	218.66	204.15	300.54	621.18	323.95	575.13	218.66	204.15	300.54	621.18	323.93	575.13	
	Short/(Excess) tax provision of earlier years	-	-	-	-	-	2.34	-	-	-	-	-	2.34	
	<b>Total Tax Expenses</b>	<b>548.66</b>	<b>559.15</b>	<b>695.54</b>	<b>1,528.18</b>	<b>2,168.95</b>	<b>2,449.47</b>	<b>529.66</b>	<b>578.15</b>	<b>695.54</b>	<b>1,528.18</b>	<b>2,168.93</b>	<b>2,449.47</b>	
7	<b>Net Profit for the period from continuing operations</b>	<b>1,556.39</b>	<b>1,493.71</b>	<b>1,932.42</b>	<b>4,257.43</b>	<b>6,195.87</b>	<b>6,993.28</b>	<b>1,242.36</b>	<b>1,682.26</b>	<b>1,930.51</b>	<b>4,231.66</b>	<b>6,192.92</b>	<b>6,964.88</b>	
	Less: Share of Profit / (Loss) transferred to Minority Interest	-	-	-	-	-	-	-	(0.14)	(0.01)	(0.14)	(0.08)	(0.08)	
8	<b>Total Profit for period</b>	<b>1,556.39</b>	<b>1,493.71</b>	<b>1,932.42</b>	<b>4,257.43</b>	<b>6,195.87</b>	<b>6,993.28</b>	<b>1,242.36</b>	<b>1,682.40</b>	<b>1,930.52</b>	<b>4,231.80</b>	<b>6,193.00</b>	<b>6,964.96</b>	
9	<b>Other Comprehensive Income (OCI)</b>													
	Items that will not be reclassified to Profit or Loss	-	-	-	-	-	(17.06)	-	-	-	-	-	(17.06)	
	Less: Income tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-	-	4.29	-	-	-	-	-	4.29	
	Other Comprehensive Income / Loss (net of taxes)	-	-	-	-	-	(12.77)	-	-	-	-	-	(12.77)	
10	<b>Total Comprehensive Income</b>	<b>1,556.39</b>	<b>1,493.71</b>	<b>1,932.42</b>	<b>4,257.43</b>	<b>6,195.87</b>	<b>6,980.51</b>	<b>1,242.36</b>	<b>1,682.40</b>	<b>1,930.52</b>	<b>4,231.80</b>	<b>6,193.00</b>	<b>6,952.19</b>	
11	<b>Other Equity Reserves</b>						59,133.51						59,104.90	
12	<b>Details of Equity Share Capital</b>													
	Paid-up equity share capital	1,002.83	1,002.83	1,002.78	1,002.83	1,002.78	1,002.78	1,002.83	1,002.83	1,002.78	1,002.83	1,002.78	1,002.78	
	Face value of equity share capital (Rs.)	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
13	<b>Earning per equity share</b>													
i	Basic earnings per share from continuing and discontinued operations	1.55	1.49	1.93	4.25	6.18	6.97	1.24	1.68	1.93	4.22	6.18	6.95	
ii	Diluted earnings per share from continuing and discontinued operations	1.55	1.49	1.93	4.25	6.18	6.97	1.24	1.68	1.93	4.22	6.18	6.95	

#### Notes:

- The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards), Rules, 2015 (Ind AS) as amended, prescribed under section 133 of Companies Act, 2013, read with rules issued thereunder.
- The above results for the quarter ended December 31, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on February 13, 2026. The Statutory Auditors have carried out limited review of the results for quarter and nine months ended December 31, 2025.
- The Company's business activity falls within a single operating segment i.e. Pharmaceuticals.
- The equity shares and basic/diluted earnings per share for the comparative period (quarter and period ended December 31, 2024) has been presented in accordance with Ind AS - 33-Earning per share.
- Previous year/quarters figures have been regrouped/reclassified, wherever necessary.

FOR GUFIC BIOSCIENCES LIMITED

PRANAV J. CHOKSI  
CEO & WHOLE TIME DIRECTOR  
DIN : 00001731

PLACE : MUMBAI  
DATE : 13/02/2026



*only for identification purpose*

**“Annexure B”**

The details as required under Regulation 30 of SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is as under:

Sr. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc.	<p>Selvax Pty Limited (“Selvax”) is an Australian Proprietary Company, Limited by Shares, engaged in health and allied services and situated in Western Australia.</p> <p>It’s a Bio-technology company, which is developing a novel immunology based treatment for large solid tumours. The technology is fully owned by Selvax and it is envisaged that successful development of the technology will provide novel cancer treatments for animals and humans.</p> <p>Highlights of the benefits from Immunotherapy application:</p> <ul style="list-style-type: none"> <li>a) Better outcome and lower toxicity should result in an improved quality of life for the cancer patient;</li> <li>b) Potentially able to overcome increased drug resistance seen in the larger tumours treated with individual immunotherapy (or chemotherapy) agents;</li> <li>c) Specifically targeting tumour site means lower doses and less side effects;</li> <li>d) Treatment in one location leads to a whole- immune body response that can clear other un-treated tumours, so this therapy can potentially be applied to patients with metastatic cancer;</li> <li>e) Potentially suitable for treating a range of solid tumour in humans and dogs</li> </ul>

		<p>including sarcomas, lung cancer, pancreatic, skin, breast, and colorectal cancer; and</p> <p>f) The induction of long term-immunological memory to protect patients against cancer recurrence.</p> <p>The total Issued Share Capital of Selvax as on June 30, 2025 is AUD 52,85,176/-.</p>
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group / group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	<p>No, this acquisition does not fall within the purview of related party transactions.</p> <p>Further, the promoter / promoter group / group companies have no interest in Selvax whose equity shares are being acquired by the Company.</p>
3.	Industry to which the entity being acquired belongs	It is a biopharma research and development company.
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	<p>The proposed acquisition of equity shares in Selvax is a strategic arrangement for the development of immunotherapy solutions in oncology and is intended to enable the Company to diversify into the healthcare and biotechnology sector and participate in the development of immunology-based treatments for large solid tumours. The investment aligns with the Company’s long-term strategy of strategic diversification and value creation, providing access to proprietary technology, research capabilities, and potential commercial opportunities in both human and veterinary oncology, and is expected to generate sustainable long-term benefits for the Company and its stakeholders once the therapy is medically commercialised.</p>

Corp. Office : SM House, 11 Sahakar Road, Vile Parle (East), Mumbai - 400 057, Tel.: (+91-22) 6726 1000,  
Fax: (+91-22) 6726 1067, Email : info@guficbio.com, Website: www.gufic.com

5.	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable
6.	Indicative time period for completion of the acquisition	Within 4 months
7.	Nature of consideration - whether cash consideration or share swap or any other form and details of the same	Cash consideration
8.	Cost of acquisition and/or the price at which the shares are acquired;	378,350 Ordinary shares at AUD 20 cents per share would be acquired at USD 50,000.
9.	Percentage of shareholding / control acquired and / or number of shares acquired	Pre-Acquisition of total number of Ordinary shares held – <b>13,07,000 shares</b> Post-Acquisition of total number of Ordinary shares held – <b>16,85,350 shares</b>
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p><b>Brief Background:</b> Selvax was incorporated on August 14, 1987. It is a biotechnology Company, which is developing a novel immunology based treatment for large solid tumours and the technology is fully owned by the Company and it is envisaged that successful development of the technology will provide novel cancer treatment for animals and humans.</p> <p><b>Country in which the acquired entity has presence:</b> Australia</p> <p><b>Total Income of last 3 years: (financial year commencing on July 01 to June 30)</b> For year ended June 30, 2025: AUD 356,972 For year ended June 30, 2024: AUD 248,817 For year ended June 30, 2023: AUD 220,435.25</p>

**Regd. Off. :** 37, First Floor, Kamala Bhavan II, S. Nityanand Road, Andheri (East), Mumbai - 400 069

**Plants :** Unit No. 1: N. H. No. 8, Near grid, Kabilpore - 396424, Navsari, Gujarat (INDIA)

Unit No. 2: Survey No. 171, N. H. No. 8, Near grid, Kabilpore - 396424, Navsari, Gujarat (INDIA)

Plot No. 48, Smart Industrial Park, Near Natrip, Pithampur, District Dhar - 454775, Madhya Pradesh  
703, Belgaum Industrial Estate, Udhyambag, Belgaum - 590008, Karnataka